|
Financial Instruments (Details) (USD $)
In Thousands, except Share data, unless otherwise specified |
9 Months Ended | 9 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Mar. 31, 2012
|
Dec. 31, 2012
Nano Vibronix [Member]
|
Dec. 31, 2012
Nano Vibronix [Member]
Convertible Promissory Note [Member]
|
Nov. 22, 2011
Nano Vibronix [Member]
Convertible Promissory Note [Member]
|
Dec. 31, 2012
Liability Warrants Having Exercise Price 30 [Member]
|
Dec. 31, 2011
Liability Warrants Having Exercise Price 30 [Member]
|
Dec. 31, 2011
Liability Warrants Having Exercise Price 72 [Member]
|
||||
| Financial Instruments [Abstract] | ||||||||||||
| Foreign currency transaction gains and (losses) | $ 0 | $ 27 | ||||||||||
| Number of open foreign exchange contracts | 0 | |||||||||||
| Class of Warrant or Right [Line Items] | ||||||||||||
| Warrants outstanding (in shares) | 285,454 | 8,348 | 8,348 | 477 | ||||||||
| Exercise price of warrants outstanding (in dollars per share) | $ 30.00 | $ 30.00 | $ 72.00 | |||||||||
| Non cash gains on warrants | 3 | 6 | ||||||||||
| Note receivable - CollabRx | 0 | |||||||||||
| Debt extinguishment as a consideration of acquisition | 300 | |||||||||||
| Promissory note liability assumed as a purchase price of acquisition | 500 | |||||||||||
| Investment [Line Items] | ||||||||||||
| Strategic investment | 337 | 312 | [1] | 300 | ||||||||
| Interest rate on convertible promissory note (in hundredths) | 10.00% | |||||||||||
| Maturity date of convertible promissory note | Nov. 15, 2014 | |||||||||||
| Convertible preferred stock | $ 3,000 | |||||||||||
| Conversion price (in dollars per share) | $ 0.284 | |||||||||||
|
||||||||||||